News >

Adjuvant Pembrolizumab Approved in EU for Stage III Melanoma

Jason M. Broderick @jasoncology
Published: Monday, Dec 17, 2018

Alexander M. M. Eggermont, MD, PhD

Alexander M. M. Eggermont,

MD, PhD
The European Commission has approved pembrolizumab (Keytruda) as an adjuvant treatment for patients with resected, stage III melanoma with lymph node involvement, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x